# A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors

> **NCT03261947** · PHASE2 · COMPLETED · sponsor: **Millennium Pharmaceuticals, Inc.** · enrollment: 101 (actual)

## Conditions studied

- Metastatic Pancreatic Cancer
- Colorectal Cancer
- Esophageal Neoplasms
- Carcinoma, Non-small-cell Lung

## Interventions

- **DRUG:** TAK-931

## Key facts

- **NCT ID:** NCT03261947
- **Lead sponsor:** Millennium Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-25
- **Primary completion:** 2020-08-24
- **Final completion:** 2020-08-24
- **Target enrollment:** 101 (ACTUAL)
- **Last updated:** 2021-09-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03261947

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03261947, "A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03261947. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*